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Abstract
Head injury is common, sometimes requires intensive care unit admission, and is associated with
significant mortality and morbidity. A gap still remains in the understanding of the molecular
mechanism of this condition. This review is aimed at providing a general overview of the molecular
mechanisms involved in traumatic brain injury to a busy clinician. It will encompass the
pathophysiology in traumatic brain injury including apoptosis, the role of molecules and genes, and
a brief mention of possible pharmacological therapies.
Introduction and epidemiology
Our understanding of the molecular mechanisms of trau-
matic brain injury (TBI) has improved over the last dec-
ade, but a gap still exists between these advances and their
translation into direct clinical care. About 0.5–1 million
patients present to hospitals in the UK with TBI. It is the
leading cause of disability in people under 40, and
severely disables 150–200 people per million annually
[1,2]. In the US, TBI affects 1.4 million people, at an esti-
mated annual cost of $56 billion [3]. Diseases of the nerv-
ous system (International Classification of Diseases-
revision 9) accounted for 8.4% of the total health and
social services net public expenditure for 1992 and 1993
in England [4]. The purpose of this review is to look at
genetic and molecular influences after an acute head
injury and the long term outcome.
Although our ability to assess and predict neurological
outcome following TBI has improved, most of the prog-
nostic tools are still poorly validated and therefore rarely
used [5]. Understanding the molecular mechanisms and
integrating these into clinical practice will help us to pre-
dict outcomes more accurately, and will also pave the way
for newer treatment modalities and further research.
Current understanding of the basic molecular mecha-
nisms resulting in neurological damage following TBI has
sparked several significant attempts to synthesise drugs
(e.g. Selfotel) [6]. So far these attempts have universally
met with little success clinically, but they have provided
some insights for future research [6]. Such research has
been hampered by a lack of translation of results from ani-
mal models into humans. Despite this it is likely that such
work, both in animal models and observational studies in
patients with acute TBI will continue to shed light in this
important subject.
Pathophysiology of brain injury
Acute TBI is characterised by two injury phases, primary
and secondary. The primary brain injury is the direct
injury to the brain cells incurred at the time of the initial
impact. This results in a series of, biochemical processes
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which then result in secondary brain injury. The primary
aim for the acute management of TBI is to limit the sec-
ondary injury. The secondary brain injury is caused by a
dynamic interplay between ischaemic, inflammatory and
cytotoxic processes. Studies with microdialysis techniques
have shown that one of the most significant factors caus-
ing secondary brain injury is the excessive release of exci-
totoxins such as glutamate and aspartate that occurs at the
time of the primary brain injury. These excitotoxins act on
the N-methyl-D-aspartate channel, altering cell wall per-
meability with an increase in intracellular calcium and
sodium and activation of calcineurin and calmodulin.
This ultimately, leads to destruction of the axon [7,8].
Potassium is also released from the cells and absorbed by
the astrocytes, in an attempt to restrict the ionic imbalance
causing swelling of the cells and ultimately cell death.
There is a complex cascade of cellular inflammatory response
following TBI which propagates secondary brain damage.
This inflammatory process lasts from hours to days contrib-
uting continuously to secondary brain damage. The inflam-
matory response resulting from an acute TBI is not limited to
the brain and multiple organ dysfunction syndromes are
commonly seen. The major molecules in the brain involved
in this cascade are growth factors, catecholamines, neuroki-
nins, cytokines and chemokines [9].
Interleukins (IL) are proinflammatory cytokines, the lev-
els of interleukins seen in intracerebral bleeds, and clini-
cal signs of inflammation at admission, have correlated
well with the magnitude of perilesional oedema and mor-
tality [10,11]. There is a rise in IL-6 and 10 in children fol-
lowing a TBI. The increased level of IL-10 was directly
related to mortality in TBI [12]. The rise in inflammatory
cytokines (e.g. IL-6) following TBI is a double edged
sword; both neurotoxicity and neuroprotection may be
induced by it. Inflammatory cytokines facilitate neurotox-
icity by encouraging excitotoxicity and the inflammatory
response, but simultaneously they facilitate the neuro-
trophic mechanisms and induction of cell growth factors
which are neuroprotective [13]. It has also been shown by
Vuylsteke et al that there is an increased gradient of
inflammatory marker IL-8 in the brain after cardiopulmo-
nary bypass, which is attenuated by hypothermia [14].
This gradient continued into the postoperative period.
The primary insult also results in an immediate distur-
bance of the cerebral circulation, resulting in cerebral
ischaemia and which contributes significantly to about
90% of deaths after closed head injuries. [15]. Ischaemic
brain damage is perpetuated by factors such as hypoten-
sion, hypoxia, raised intracranial pressure, oedema, focal
tissue compression, damage to microvasculature, and in
late phases, vasospasm in the remaining vessels [16,17].
The time sequence after TBI can be arbitrarily divided into
an early (phase 1, immediate, with hypoperfusion), inter-
mediate (phase 2, on days 1–3, when hyperaemia can be
seen) and a late vasospastic phase (phase 3, on days 4–15,
with a marked reduction in blood flow) [17]. These differ-
ent phases are associated with marked regional variations
in cerebral blood flow, with a reduction in blood flow to
the surrounding of the ischaemic core, which does not
respond to augmentation of cerebral perfusion pressure
[18].
Surviving apoptosis
Programmed cell death (which is often referred to as apopto-
sis although strictly speaking this refers to the distinct mor-
phological changes after programmed cell death) is a genetic
mechanism by which cells are eliminated during develop-
ment, and is the physiological mechanism by which cells are
normally removed in the adult animal [19]. This involves
specific genes and proteins which were first described in neu-
ronal development of the round worm [20]. Following TBI
there is increased expression of two main sets of genes which
are genes encoding for the caspase family of cysteine pro-
teases [including interleukin-1β converting enzyme (ICE)
and cpp32] and a family of genes that are homologous to the
oncogene Bcl-2 that either promote or suppress cell death.
The Bcl-2 gene family controls both caspase dependent and
independent apoptosis. [19,21-23]. The endpoint of all
these steps is fragmentation of cellular DNA with collapse of
the nuclear structure, followed by the formation of mem-
brane-wrapped apoptotic bodies, cleared by macrophages
[24].
Apoptosis is now recognised as an important factor in sec-
ondary brain injury [25]. Following TBI, two different
types of cells are visible; type 1 and 2 cells. The type 1 cells
show a classic necrotic pattern (this follows the primary
brain injury) and type 2 cells shows a classic apoptotic
pattern on microscopy [25,19]. Cells undergoing apopto-
sis die without membrane rupture and therefore elicit less
inflammatory reactions. This is in contrast to the cells
undergoing necrosis [26]. There is therefore a suggestion
that neuronal apoptosis after TBI may be a protective
response by the brain in order to remove injured tissue
cells whilst having little effect on remaining brain tissue
[27]. Apoptotic cells have been identified within contu-
sions in the acute post-traumatic period, and in regions
remote from the site of injury days and weeks after
trauma.
Pharmacological strategies to reduce apoptotic cell death
have been investigated, [28] For example, rats treated with
the caspase-3 inhibitor N-benzyloxycarbonyl-Asp-Glu-
Val-Asp-fluoromethylketone (DEVD) demonstrate a 30%
reduction in lesion volume measured 3 weeks after TBI
when compared with vehicle-treated controls [19].
Long term pathophysiology
Recent advances in the management of severe acute TBI has
resulted in improved outcomes for patients who might pre-
viously have had poor outcomes. In particular the manage-World Journal of Emergency Surgery 2009, 4:7 http://www.wjes.org/content/4/1/7
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ment of such patients in specialist units has had a
significant impact, although the definitive factors contrib-
uting to improved outcomes remain elusive. [29]. In recent
years there has been increasing interest in elucidating the
long term problems experienced by patients following TBI.
Further, there have been reports of people developing
dementia-like symptoms following relatively minor head
injuries (Brain injury with a GCS greater than 13 and with-
out loss of consciousness, as well as an increased incidence
of post traumatic stress disorders and depression [30]. TBI
causes a generalised atrophy of brain which is proportional
to the severity of the injury. [31]. The mechanisms for this
are yet to be fully determined. In rats it has been shown that
there are multiple antibodies to the amyloid precursor pro-
tein and amyloid precursor protein-like proteins for up to
six months, which predisposes them to degeneration of the
striatum and corpus callosum. This degeneration then
leads to progressive brain atrophy and calcifications [32].
In moderate to severe TBI there is a high incidence of hip-
pocampal atrophy which predisposes patients to cognitive
decline. When anoxic brain damage was compared to TBI
there was no overwhelming evidence of localised nerve
damage. This supports the theory that the final mechanism
for neurological injury is the same irrespective of the type
of initial insult [33].
Surviving the ischaemic insult: the role of genes
Surprisingly humans are made up of only 20,000 – 25,000
protein-coding genes, and these genes have profound
implications on our survival [34]. The genetic constituents
not only modify the risk of development of disease and its
severity, but also the ability of an organ to repair, heal and
function after an injury. In head injured patients the out-
comes are variable and cannot easily be predicted. This var-
iability cannot be fully explained by clinical features or by
the character of the injury [35]. One of the mechanisms
which could explain this is genetic polymorphism. This
may also contribute to variability in outcome in the acute
response, and functional recovery. A greater understanding
of the genetics could aid in the prediction of outcomes and
could be targeted for treatment strategies.
Studies in animals using cDNA microarray hybridization
technique have shown differential regulation of 86 genes
(seven classes) which take part in the physiological and
pathological response to TBI. The key classes they encom-
pass include transcription factors, signal transduction
genes and inflammatory proteins [36]. Such changes in
gene expression are interlinked with both disease proc-
esses (for example IL-6 and haemoxygenase-1), and out-
come in TBI.
Genes regulating the inflammatory process
Genetic polymorphisms which involve interleukin-6 (IL-
6) and haemoxygenase -1 (HO-1) may influence the
inflammatory effects seen after TBI [37]. There are two
genetic polymorphisms associated with increased IL-6 lev-
els in blood -174G>C and -572G>C, the presence of
which not only increased the risk of development of cor-
onary and cerebral aneurysms but also increased the mor-
tality when they ruptured [38]. Haemoxygenase is a rate-
limiting enzyme in haem catabolism and the inducible
form of haemoxygenase is haemoxygenase-1 (HO-1).
There is an increased expression of HO-1 in the injured rat
brain model. The end product molecules influence tissue
redox homeostasis under a wide range of pathophysiolog-
ical conditions including TBI [38].
Genes regulating the vascular responses
Cerebral ischaemia results in an activation of the hypoxia-
inducible factor-1 and 2 (HIF 1&2) genes. HIF-1 activates
the transcription of numerous genes including vascular
endothelial growth factor (VEGF), glucose transporter-1
(Glut1), Epo, transferrin (Tf), and the transferrin receptor
(TfR) all of which have been shown to be neuroprotective
in animal models after TBI [39]. Vascular endothelial
growth factor (VEGF) is the main regulator of angiogen-
esis, and in the normal adult brain and is predominantly
expressed in the epithelial cells of the choroid plexus,
astrocytes and neurons (such as granule cells of the cere-
bellum) [40]. Following cerebral ischaemia there is upreg-
ulation of both VEGFR-2 and VEGF expression. [41].
Somewhat confusingly HIF-1 upregulation and increased
VEGF expression have been associated with the develop-
ment of cerebral oedema and neuronal death following
brain injury [Chen et al, 2008, Neurobiology of Disease]
whilst also being implicated in peri infarct neuroprotec-
tion [42] Deficiencies of HIF genes in mice are associated
with embryonic death due to cardiac, vascular, and neural
malformations [43].
Genes regulating the neuronal response to TBI
Apolipoprotein epsilon (APOE) is a multifunctional pro-
tein involved predominantly in the transport of choles-
terol, maintenance of microtubules, neurones, and neural
transmission. This gene is important in the neuronal
response of the brain to injury and in the subsequent
repair processes. There are three different variants (ε2, ε3,
and ε4) to this gene and the variant ε4 situated on chro-
mosome 19 is associated with the development of Alzhe-
imer's disease, and predisposes to worse outcome in TBI
[44-46].
The presence APOE-ε4 is associated with a poor outcome
in cognitive dysfunction and functionality following
brain injury rehabilitation [47-49]. It is also associated
with a rapid cognitive decline in Alzheimer's disease [50]
and in autopsy studies has been demonstrated to incur a
significantly increased risk of development of cerebral
amyloid angiopathy [51]. In larger retrospective studies of
outcome following TBI, the presence of APOE-ε4 corre-
lates with a significantly worse outcome in young patiensWorld Journal of Emergency Surgery 2009, 4:7 http://www.wjes.org/content/4/1/7
Page 4 of 6
(page number not for citation purposes)
(aged 0–15 years). This correlation reduces with age, with,
neutralisation at 55 years [45].
The P53 gene is important in the regulation of apoptosis;
this gene exhibits a common polymorphism that results
in either proline or arginine at amino acid 72. Arg/Arg
genotype of the Arg72Pro polymorphism in p53 is associ-
ated with an increased likelihood of a poor outcome at
discharge from the surgical intensive care unit following
TBI. [52]
Genes regulating the catecholamines
There are three isoforms of the enzyme catechol-o-meth-
yltransferase (COMT) encoded by 3 genetic polymor-
phisms (COMT Val/Val, COMT Val/Met, and COMT Met/
Met). This enzyme is associated with inactivation of
dopamine and norepinephrine and is thought to func-
tionally modulate dopamine neurons, thus influencing
frontal-executive functioning. In a study by Lipsky et al
(2005) in patients with TBI, polymorphism (Val/Val), and
presumably lower cortical DA levels, resulted in worse
performance on the Wisconsin Card Sorting Test com-
pared to patients with the low activity polymorphism
(Met/Met) and presumably higher cortical DA levels [53].
Pharmacological therapies
A variety of pharmacological agents have been trialed, all
of which have shown promising results in animal models,
but when translated into the clinical setting have univer-
sally failed to influence outcome following TBI. These
agents include Selfotel, Cerestat, CP 101–606, D-CPP-ene,
Steroids, tirilazad, PEG-SOD, IGF-1/growth hormone,
Nimodipine, Bradycor, Dexanabinol, SNX-III, and anti-
convulsants (such as Valproate and Magnesium Sul-
phate). The neuroprotective actions of these agents result
from a variety of mechanisms of action, including antag-
onism of glutamate (Selfotel and CP 101–606), and free
radical scavenging (PEG-SOD) [6].
Dexanabinol is a synthetic chemical analogue of the active
component of marijuana. It is a non-competitive inhibi-
tor of the NMDA receptor, a free radical scavenger and
antioxidant, and an inhibitor of the pro-inflammatory
cytokine TNF alpha [6].
Steroids are used with good effect in the treatment of brain
oedema associated with brain tumours, and have been
shown in laboratory studies to reduce free radical produc-
tion and have a protective effect on the brain. However, sev-
eral clinical studies in TBI have shown no clear beneficial
effect on outcome or intracranial pressure [6].
Catecholamines
One of the key factors in the management of TBI is main-
tenance of cerebral perfusion pressure and cerebral blood
flow, and systemic administration of catecholamines is
often used to achieve this. Circulating endogenous cate-
cholamines are increased in TBI due to stimulation of the
sympatho-adrenal axis. Endogenous circulating catecho-
lamines are a readily quantifiable marker that predicts the
outcome in TBI [52,54]. It has been shown in rodents that
optimal synthesis of catecholamines in the brain is critical
to a working memory. TBI results in activation of tyrosine
hydroxylase (TH) in the brain. This is the rate limiting step
in catecholamine synthesis and changes in activation of
TH result in altered catecholamine signalling in the pre-
frontal cortex which impacts on memory [55].
Neurotrophins
Neurotrophins are normally found in cell bodies and the
projections of neurons, and they facilitate neuronal sur-
vival and differentiation [56,57]. They include nerve
growth factor (NGF), brain-derived neurotrophic factor
(BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4)
and neurotrophin-5 (NT-5). Of the neurotrophic agents,
BDNF shows the most promise in the future management
of brain injury. Animals treated with BDNF following TBI,
showed an improvement in cognitive function and regen-
eration of the neural network which resembled develop-
mental neuroplasticity. This was directly related to
improvement in synchronized movement and spatial ori-
entation [58,59]. Unfortunately there is no convincing
evidence for the use of these drugs in humans [60].
Conclusion
This review emphasises that the molecular mechanisms
underlying secondary brain damage following TBI are
complex. Our understanding of these mechanisms has
increased significantly in recent years, but is far from com-
plete. Advances in the acute management of TBI, is likely
to be dependant both on an improved understanding of
these mechanisms, as well as the translation of such
knowledge into the development of new molecules and
techniques to improve the clinical outcome.
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